Baxter International Inc.(BAX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$20.72
52-Week Range
$15.73 – $31.75
YTD
+6.26%
IV Rank (30D)
2.92
Straddle Price
$1.60
P/C Vol Ratio
1.74
Market Cap
$10.8B
Fair Value
-10.4% vs price
Confidence: 52% Alpha Score: 0.08

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.53%
Beta vs SPY1.00
Cost of Equity (CAPM)10.03% (VRP-adj)
WACC7.57%
Volatility Risk Premium+17.6pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-3.9%
DCF Horizon5 years explicit + fade
Free Cash Flow (TTM)$0.7B
Return on Equity (TTM)-17.2%
Book / Price57.1% — banking bias active (P/B is primary)
Gross Margin (TTM)30.1%
FCF Margin (TTM)6.4%
Debt / Equity1.43
Quality Score1/6 — cyclical/struggling (5y DCF)
Market-Implied Growth+6.1% (reverse-DCF on current price)
SMA 50$18.13 (Market Anchor value)
SMA 20 / Bollinger Mid$18.97
Bollinger Width / SMA2088.7% (drives anchor stability)
Net Debt$6.6B
Market Cap$11B
Peers used for multiples: CNC, EW, HUM, SOLV, UNH (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$18.69
Current Price
$20.86
Deviation
-10.4%
Forward-Return Rank SHORT gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -2.3% +0.18 -0.52 73.2%
42d -5.0% -0.13 -0.52 73.2%
63d -7.3% -0.47 -0.52 73.2%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF $8.42 32%
DDM (Gordon) $1.38 0%
Peer P/E n/a 0% median 34.7× · 4 peers
Peer EV/EBITDA $25.79 10% median 19.1× · 5 peers
Peer P/B $33.01 13% median 2.8× · 5 peers
Peer P/S $18.06 13% median 0.8× · 5 peers
Market Anchor (SMA50) $18.13 0% stability 0% (BB-width)
Options Expected (B-L 30d) $21.49 32% 26 strikes · skew -0.24
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
Industry (SIC)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841)
Exchange
XNYS
Market Cap
$10.8B

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan +1.98% 23
Feb +0.54% 23
Mar +1.07% 23
Apr +0.96% 23
May -1.49% 23
Jun +1.74% 23
Jul +1.59% 22
Aug -0.14% 22
Sep -0.72% 23
Oct -3.07% 23
Nov +0.52% 23
Dec +1.35% 23
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $19.12
SMA 50: $18.21
SMA 200: $19.77
Current: $20.86
EMA 12: $19.67
EMA 26: $19.03
MACD: 0.6335 | Signal: 0.1732
BULLISH
ADX (14): 21.04
WEAK TREND
+DI: 34.48
−DI: 14.38
Momentum Oscillators
RSI (14): 70.71
OVERBOUGHT
Stoch %K: 85.16
Stoch %D: 83.27
Williams %R: -4.17
Volume & Volatility
BB Upper: $20.82
BB Lower: $17.42
OVERBOUGHT
OBV: 43,960,056
Vol SMA 20: 6,876,439
Vol ROC: -10.22%
ATR: $0.71
True Range: $0.64
HV 20: 31.5%
HV 30: 35.2%
HV 60: 38.8%

Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:18.147000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BEARISH (Confidence Level: 6/10)

Key Drivers:

  • Recent negative news headlines on supply chain disruptions, manufacturing issues, and potential costs increases for critical medical supplies
  • Overbought RSI indicator and high volatility readings suggest a pullback or consolidation phase

Primary Risks:

  • Continued supply chain disruptions impacting revenue and profitability
  • Increased competition in the IV solutions market

Investment Thesis:

BAX is likely to experience a short-term correction due to recent negative news and overbought technical indicators. However, its strong brand presence and growing demand for IV solutions could lead to a rebound once the market settles.

Recent News Sentiment Impact:

The recent news headlines have had a bearish impact on BAX's stock price, with a focus on supply chain disruptions, manufacturing issues, and potential costs increases. This negative sentiment has contributed to the overbought RSI reading.

Technical Analysis

Trend Direction:

  • Short-term: BEARISH (1-4 weeks)
  • Medium-term: NEUTRAL (1-3 months)
  • Long-term: BULLISH (3-12 months)

Support/Resistance Levels:

  • Key resistance levels: $21.25, $22.50
  • Key support levels: $19.00, $17.50

Momentum Signals:

  • RSI interpretation: OVERBOUGHT (>70), suggesting a potential pullback or consolidation phase
  • MACD signal: BULLISH (above the signal line)
  • Bollinger Bands position: OVERBOUGHT (price touching upper band)

Volume Analysis:

  • Volume trends: Increasing volume on recent price declines suggests institutional selling
  • Institutional interest signals: High put/call ratios and unusual activity suggest bearish sentiment

News & Sentiment Analysis

Recent Headlines Summary:

The past 10 news articles have highlighted supply chain disruptions, manufacturing issues, and potential costs increases for critical medical supplies. This negative news has contributed to the overbought RSI reading.

Sentiment Assessment: NEGATIVE

Catalyst Identification:

  • Upcoming earnings release
  • Regulatory changes affecting the IV solutions market

Market Narrative:

The recent news headlines have aligned with a bearish narrative, suggesting potential short-term weakness for BAX. However, the company's strong brand presence and growing demand for IV solutions could lead to a rebound once the market settles.

Risk & Volatility Assessment

Beta Interpretation: HIGH (1.24 vs SPY), indicating high risk relative to the market

Volatility Regime:

  • Current volatility levels are higher than historical averages, suggesting a more volatile environment

Options Market Signals:

  • IV rank: 2.9% (Low)
  • Put/call ratios: Bearish sentiment
  • Unusual activity: High put buying suggests institutional selling

Downside Protection:

  • Support levels: $19.00, $17.50
  • Risk management considerations: Stop-loss levels and position sizing considerations

Market Context & Positioning

Sector Performance:

  • Relative strength vs sector/market: Weakest performer in the medical equipment sector

Institutional Activity:

  • Volume patterns suggesting institutional selling: Increasing volume on recent price declines

Correlation Analysis:

  • R-squared interpretation: BAX has a low correlation with the broader market, suggesting potential for deviations from the overall trend

Relative Valuation:

  • Position within trading range: Oversold and below its 50-day moving average, suggesting potential for a rebound

Key Levels & Action Items

Critical Price Levels:

  • Support/resistance to monitor: $19.00, $17.50, $21.25, $22.50

Breakout/Breakdown Levels:

  • Technical levels that could trigger significant moves: $18.50, $16.50

Time-Sensitive Catalysts:

  • Upcoming earnings release
  • Regulatory changes affecting the IV solutions market

Risk Management:

  • Stop-loss levels and position sizing considerations: Use a stop-loss at $19.00 and consider scaling out of positions if BAX breaks below this level.

By considering both technical and fundamental analysis, as well as recent news headlines, we believe that BAX is likely to experience a short-term correction due to recent negative news and overbought technical indicators. However, its strong brand presence and growing demand for IV solutions could lead to a rebound once the market settles.

Generated 2026-06-13 13:16 UTC
Earnings History
5 of 8 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-06 After-Close 2.03% 0.89% 0.44x Within
2024-11-08 Pre-Market 6.27% 5.46% 0.87x Within
2025-02-03 After-Close 3.06% 1.32% 0.43x Within
2025-05-01 Pre-Market 5.75% 1.84% 0.32x Within
2025-07-31 Pre-Market 4.01% 22.21% 5.54x Exceeded
2025-10-30 Pre-Market 10.04% 14.54% 1.45x Exceeded
2026-02-12 Pre-Market 10.27% 15.99% 1.56x Exceeded
2026-04-30 After-Close 3.84% 2.10% 0.55x Within
Options Activity
IV Rank (30D)
2.92
IV Rank (7D)
100
Avg IV
52.1%
Straddle (30D)
$1.60
Straddle (7D)
$1.32
P/C Volume
1.74
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.24
Correlation (SPY)
32.9%
0.11
Ann. Volatility
46.5%
SPY Volatility
12.3%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 514,000,000 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

682 filers532,645,786 shares$8.90B value103.63% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 79,400,664 $1.33B 14.99% 15.45% 2026-03-31
2 VANGUARD GROUP INC Custodian 62,635,136 $1.20B 13.45% 12.19% 2025-12-31
3 PZENA INVESTMENT MANAGEMENT LLC 64,527,823 $1.08B 12.18% 12.55% 2026-03-31
4 DODGE & COX 57,254,570 $961.88M 10.81% 11.14% 2026-03-31
5 FMR LLC Custodian 46,264,804 $777.25M 8.73% 9.00% 2026-03-31
6 STATE STREET CORP 19,979,957 $335.86M 3.77% 3.89% 2026-03-31
7 GREENHAVEN ASSOCIATES INC 14,307,688 $240.37M 2.70% 2.78% 2026-03-31
8 GEODE CAPITAL MANAGEMENT, LLC Custodian 13,762,965 $230.82M 2.59% 2.68% 2026-03-31
9 Invesco Ltd. Custodian 13,121,171 $220.44M 2.48% 2.55% 2026-03-31
10 MORGAN STANLEY Custodian 8,615,885 $164.65M 1.85% 1.68% 2025-12-31
11 First Pacific Advisors, LP 6,700,925 $112.58M 1.26% 1.30% 2026-03-31
12 EQUITY INVESTMENT CORP 6,369,994 $107.02M 1.20% 1.24% 2026-03-31
13 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 6,225,060 $104.58M 1.18% 1.21% 2026-03-31
14 BANK OF AMERICA CORP /DE/ Custodian 6,166,133 $103.59M 1.16% 1.20% 2026-03-31
15 DIMENSIONAL FUND ADVISORS LP Custodian 5,931,791 $99.62M 1.12% 1.15% 2026-03-31
16 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 5,589,554 $93.90M 1.06% 1.09% 2026-03-31
17 Artisan Partners Limited Partnership 4,861,774 $81.68M 0.92% 0.95% 2026-03-31
18 NORTHERN TRUST CORP Custodian 4,347,318 $73.03M 0.82% 0.85% 2026-03-31
19 UBS Group AG Custodian 4,319,497 $72.57M 0.82% 0.84% 2026-03-31
20 GOLDMAN SACHS GROUP INC Custodian 3,869,555 $65.01M 0.73% 0.75% 2026-03-31
21 Russell Investments Group, Ltd. Custodian 3,435,016 $57.50M 0.65% 0.67% 2026-03-31
22 RWC Asset Management LLP 3,077,569 $51.70M 0.58% 0.60% 2026-03-31
23 Bank of New York Mellon Corp Custodian 2,623,255 $44.07M 0.50% 0.51% 2026-03-31
24 FIL Ltd 2,589,163 $43.50M 0.49% 0.50% 2026-03-31
25 EDMOND DE ROTHSCHILD HOLDING S.A. 2,493,164 $41.89M 0.47% 0.49% 2026-03-31
18 filers$75.14M notional
# Filer Notional Value % of Total Period
1 Great Hill Capital LLC $22.60M 30.08% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $10.77M 14.33% 2026-03-31
3 MILLENNIUM MANAGEMENT LLC Custodian $8.46M 11.26% 2026-03-31
4 JANE STREET GROUP, LLC Custodian $6.98M 9.29% 2026-03-31
5 CITADEL ADVISORS LLC Custodian $6.53M 8.69% 2026-03-31
6 NOMURA HOLDINGS INC $4.93M 6.56% 2026-03-31
7 Point72 Asset Management, L.P. $3.30M 4.39% 2026-03-31
8 Squarepoint Ops LLC $2.54M 3.38% 2026-03-31
9 WOLVERINE TRADING, LLC Custodian $2.49M 3.32% 2025-09-30
10 Walleye Capital LLC $1.65M 2.20% 2026-03-31
11 CAPITAL FUND MANAGEMENT S.A. $1.46M 1.95% 2026-03-31
12 Walleye Trading LLC $1.03M 1.37% 2026-03-31
13 Cubist Systematic Strategies, LLC $812.89K 1.08% 2025-09-30
14 CAPSTONE INVESTMENT ADVISORS, LLC $618.24K 0.82% 2026-03-31
15 CONTINENTAL ADVISORS LLC $504.00K 0.67% 2026-03-31
16 INSPIRION WEALTH ADVISORS, LLC $369.60K 0.49% 2026-03-31
17 Arkadios Wealth Advisors $70.56K 0.09% 2026-03-31
18 MARSHALL WACE, LLP Custodian $11.76K 0.02% 2026-03-31
16 filers$87.78M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $50.25M 57.24% 2026-03-31
2 CITADEL ADVISORS LLC Custodian $9.71M 11.06% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $6.67M 7.60% 2026-03-31
4 Point72 Asset Management, L.P. $5.01M 5.71% 2026-03-31
5 Walleye Trading LLC $3.88M 4.42% 2026-03-31
6 MILLENNIUM MANAGEMENT LLC Custodian $3.84M 4.38% 2026-03-31
7 WOLVERINE TRADING, LLC Custodian $1.83M 2.09% 2025-09-30
8 Parallax Volatility Advisers, L.P. $1.48M 1.69% 2026-03-31
9 Squarepoint Ops LLC $1.10M 1.25% 2026-03-31
10 CAPITAL FUND MANAGEMENT S.A. $1.08M 1.23% 2026-03-31
11 Walleye Capital LLC $930.72K 1.06% 2026-03-31
12 CAPSTONE INVESTMENT ADVISORS, LLC $845.04K 0.96% 2026-03-31
13 TUDOR INVESTMENT CORP ET AL $529.20K 0.60% 2026-03-31
14 Caption Management, LLC $359.52K 0.41% 2026-03-31
15 Cubist Systematic Strategies, LLC $266.41K 0.30% 2025-09-30
16 MARSHALL WACE, LLP Custodian $8.40K <0.01% 2026-03-31
Insider Activity
Latest: 2026-06-03
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-03 James Teaff President, CCS Tax (F) −321 $18.68 -$6.0K EDGAR
2026-06-03 Steven P. Wallace President, Adv. Surgery Tax (F) −153 $18.68 -$2.9K EDGAR
2026-06-03 Anita A Zielinski SVP, Interim CFO, CAO & Cntrlr Award (A) +13,426 EDGAR
2026-05-07 William A. II Ampofo Director Award (A) +12,836 EDGAR
2026-05-07 Jeffrey A Craig Director Award (A) +12,836 EDGAR
2026-05-07 Michael R. McDonnell Director Award (A) +12,836 EDGAR
2026-05-07 David Brent Shafer Director Award (A) +12,836 EDGAR
2026-05-07 PATRICIA MORRISON Director Award (A) +12,836 EDGAR
2026-05-07 NANCY M SCHLICHTING Director Award (A) +12,836 EDGAR
2026-05-07 Amy McBride Wendell Director Award (A) +12,836 EDGAR
2026-05-07 David S. Wilkes Director Award (A) +12,836 EDGAR
2026-03-10 Joel T. Grade EVP and CFO Tax (F) −8,153 $17.69 -$144.2K EDGAR
2026-03-10 Reazur Rasul EVP,Group Pres,Healthcare Tax (F) −12,674 $17.69 -$224.2K EDGAR
2026-03-10 David S. Rosenbloom EVP and General Counsel Tax (F) −6,620 $17.69 -$117.1K EDGAR
2026-03-10 Maria Cecilia Soriano Group Pres., ITT & Pharma. Tax (F) −2,848 $17.69 -$50.4K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
79 insiders · @ $20.86
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Third Point LLC Director 36,001,790 $751.00M -$642.30M 1 2017-11-07
2 Daniel S Loeb Director 23,008,124 $479.95M -$3.05B 6 2019-05-17
3 ROBERT L JR PARKINSON Chairman of the Board and CEO 689,991 $14.39M -$86.37M 22 2015-08-13
4 Andrew P. Hider President and CEO 572,239 $11.94M $0 2 2026-03-03
5 JOSE E ALMEIDA Chairman, CEO, President 568,565 $11.86M $499.8K 23 2024-12-17
6 Joel T. Grade EVP and CFO 271,674 $5.67M $0 9 2026-03-10
7 Jeanne K Mason EVP, Chief HR Officer 199,853 $4.17M -$26.00M 57 2025-12-16
8 JAMES SACCARO EVP, Chief Financial Officer 177,899 $3.71M $0 23 2023-03-06
9 Heather Knight EVP, Chief Operating Officer 177,362 $3.70M $0 11 2025-03-10
10 JAMES M GATLING Corporate Vice President 163,092 $3.40M -$18.45M 17 2011-03-08
11 David S. Rosenbloom EVP and General Counsel 138,216 $2.88M $0 12 2026-03-10
12 Alok Sonig EVP,Group President,Pharma 128,219 $2.67M $0 8 2025-09-04
13 Robert M Davis Corporate Vice President 125,899 $2.63M -$16.95M 24 2014-03-06
14 Reazur Rasul EVP,Group Pres,Healthcare 125,557 $2.62M $0 14 2026-03-10
15 LUDWIG HANTSON Corporate Vice President 109,990 $2.29M -$4.81M 19 2015-06-03
16 Christopher A. Toth EVP, Group Pres, Kidney Care 105,186 $2.19M $0 5 2025-02-04
17 Cristiano Franzi SVP, President, EMEA 102,145 $2.13M -$4.08M 17 2023-03-06
18 David P. Scharf CVP and General Counsel 102,087 $2.13M -$5.77M 19 2017-02-23
19 JOHN J GREISCH Corporate Vice President 86,868 $1.81M -$9.04M 13 2009-03-18
20 ROBERT J. HOMBACH Corporate Vice President 83,031 $1.73M -$3.51M 12 2015-03-05
21 JOY A AMUNDSON Corporate Vice President 81,665 $1.70M $0 9 2010-03-17
22 Giuseppe Accogli EVP, Chief Operating Officer 76,495 $1.60M -$13.14M 26 2022-03-04
23 Maria Cecilia Soriano Group Pres., ITT & Pharma. 75,045 $1.57M $0 3 2026-03-10
24 David Brent Shafer Interim CEO and Chair 72,804 $1.52M $0 6 2026-05-07
25 James W Borzi EVP,Chief Supply Chain Officer 71,948 $1.50M $0 15 2025-09-04
26 Brik V Eyre SVP, President, Americas 71,475 $1.49M -$19.05M 22 2019-03-04
27 Steven P. Wallace President, Adv. Surgery 70,128 $1.46M $0 1 2026-06-03
28 Peter J Arduini Corporate Vice President 68,975 $1.44M -$3.20M 13 2010-03-17
29 Brian Stevens SVP, CAO & Controller 67,538 $1.41M -$213.8K 26 2024-03-08
30 JEAN LUC BUTEL Corporate Vice President 62,316 $1.30M $0 7 2014-03-06
31 Anita A Zielinski SVP, Interim CFO, CAO & Cntrlr 59,714 $1.25M $0 4 2026-06-03
32 NORBERT G RIEDEL Corporate Vice President 56,689 $1.18M -$25.15M 17 2013-01-18
33 KORNELIS J. STORM Director 53,322 $1.11M -$4.37M 16 2018-03-30
34 Sean Martin SVP and General Counsel 52,632 $1.10M -$6.13M 15 2022-03-04
35 Bruce McGillivray Corporate Vice President 52,566 $1.10M -$12.73M 11 2010-03-17
36 Paul Vibert CVP, International 51,283 $1.07M $0 9 2017-03-08
37 Jill M Schaaf CVP, Renal 48,608 $1.01M $0 6 2016-03-09
38 Amy McBride Wendell Director 44,235 $922.7K $0 10 2026-05-07
39 JAMES R III GAVIN Director 43,618 $909.9K -$5.10M 68 2020-09-15
40 PATRICIA MORRISON Director 42,386 $884.2K $0 9 2026-05-07
41 ALBERT P L STROUCKEN Director 37,531 $782.9K -$2.68M 26 2023-03-22
42 David S. Wilkes Director 37,076 $773.4K $0 7 2026-05-07
43 Stephen N. Oesterle Director 35,847 $747.8K $0 10 2025-05-08
44 Marcus Schabacker CVP, Chief Scientific Officer 35,602 $742.7K $0 9 2017-03-08
45 NANCY M SCHLICHTING Director 34,994 $730.0K $0 6 2026-05-07
46 Timothy P Lawrence CVP, Operations 34,478 $719.2K $0 5 2016-03-09
47 THOMAS T STALLKAMP Director 34,176 $712.9K -$6.63M 29 2021-05-06
48 GAIL D FOSLER Director 32,566 $679.3K -$3.01M 10 2015-05-07
49 Cheryl L White Corporate Vice President 31,401 $655.0K -$2.28M 11 2010-03-17
50 Robert Felicelli CVP, Business Transformation 31,386 $654.7K $0 41 2017-01-03
51 Michael J Baughman Corporate Vice President 31,180 $650.4K -$4.59M 18 2013-01-18
52 Steven Flynn SVP, President, APAC 31,080 $648.3K $0 2 2023-03-03
53 James Teaff President, CCS 31,063 $648.0K $0 1 2026-06-03
54 PETER S HELLMAN Director 30,895 $644.5K -$2.55M 35 2022-05-05
55 William A. II Ampofo Director 30,375 $633.6K $0 4 2026-05-07
56 Cathy R Smith Director 30,345 $633.0K $0 9 2025-05-08
57 Michael F Mahoney Director 30,089 $627.7K $0 10 2023-05-04
58 Cynthia Carlisle Executive Vice President, CHRO 29,677 $619.1K $0 1 2026-03-03
59 JOHN D FORSYTH Director 27,029 $563.8K -$3.05M 33 2022-04-05
60 WALTER E BOOMER Director 25,002 $521.5K -$4.18M 7 2011-05-05
61 Thomas F Chen Director 24,914 $519.7K -$142.0K 39 2022-05-05
62 Phillip L. Batchelor Corporate Vice President 24,632 $513.8K -$1.68M 14 2014-03-06
63 Jeffrey A Craig Director 23,662 $493.6K $0 3 2026-05-07
64 SUSAN R LICHTENSTEIN Corporate Vice President 23,191 $483.8K $0 7 2009-03-18
65 Karenann K Terrell Corporate Vice President 22,822 $476.1K $0 12 2010-03-17
66 Jacqueline Kunzler SVP, Chief Quality Officer 22,625 $472.0K -$725.0K 18 2023-03-06
67 Andrew Frye SVP, President, APAC 22,002 $459.0K -$1.57M 14 2022-03-04
68 Sebastian J Bufalino CVP, Controller 21,561 $449.8K -$3.39M 17 2016-03-07
69 Scott Pleau SVP, Operations 20,076 $418.8K -$3.58M 11 2019-04-02
70 Blake E Devitt Director 19,892 $414.9K -$393.3K 11 2015-05-07
71 JOSEPH B MARTIN Director 16,525 $344.7K -$1.34M 7 2010-10-27
72 STEPHEN H RUSCKOWSKI Director 16,499 $344.2K $0 3 2025-05-08
73 Carole J Shapazian Director 15,968 $333.1K -$5.10M 31 2018-12-17
74 Michael R. McDonnell Director 14,647 $305.5K $0 2 2026-05-07
75 PETER M WILVER Director 13,267 $276.7K $0 3 2024-05-09
76 Caroline Karp SVP, Controller 12,734 $265.6K $0 8 2018-03-07
77 WAYNE T HOCKMEYER Director 12,359 $257.8K $0 8 2015-05-07
78 UMA CHOWDHRY Director 9,874 $206.0K $0 5 2016-05-05
79 Thomas Fang-Tyan Chen Director 790 $16.5K $0 1 2012-11-14
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Recent SEC Filings
Latest: 2026-05-08
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-08 0001193125-26-214680 EDGAR
2026-04-30 0001628280-26-028582 EDGAR
2026-03-19 0001193125-26-116114 EDGAR
2026-03-16 0001193125-26-107345 EDGAR
2026-02-12 0001628280-26-007474 EDGAR
2025-12-22 0000010456-25-000025 EDGAR
2025-12-04 0001628280-25-055359 EDGAR
2025-11-25 0001628280-25-054015 EDGAR
2025-11-19 0001628280-25-053056 EDGAR
2025-11-19 0001628280-25-053187 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-12 0001628280-26-007733 EDGAR
2025-02-21 0001628280-25-007201 EDGAR
2024-02-08 0001628280-24-003932 EDGAR
2023-02-09 0001628280-23-002864 EDGAR
2022-02-23 0001628280-22-003432 EDGAR
2021-02-11 0001628280-21-001867 EDGAR
2020-03-17 0001628280-20-003693 EDGAR
2019-02-21 0001564590-19-003727 EDGAR
2018-02-23 0001564590-18-002954 EDGAR
2017-02-23 0001564590-17-002240 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-04-30 0001628280-26-028962 EDGAR
2025-11-04 0001628280-25-048897 EDGAR
2025-08-05 0001628280-25-037877 EDGAR
2025-05-06 0001628280-25-022727 EDGAR
2024-11-12 0001628280-24-047221 EDGAR
2024-08-06 0001628280-24-034965 EDGAR
2024-05-02 0001628280-24-019786 EDGAR
2023-11-02 0001628280-23-036195 EDGAR
2023-07-27 0001628280-23-025825 EDGAR
2023-04-27 0001628280-23-013357 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio1.8
P/S Ratio0.9
EV/EBITDA17.3
TTM Revenue$11.3B
TTM Net Income$-1.0B
TTM EPS$-2.02
ROE-17.2%
Dividend Yield2.51%
Debt/Equity1.57